Diamondback Energy's $26 billion acquisition of Endeavor Energy Resources will solidify their positions in the shale oil drilling market. Meanwhile, ...
Shares of G1 Therapeutics plunged 46% after disappointing results from their Phase 3 trilaciclib combination trial for triple-negative breast cancer. ...